Drug Discovery Service Market Size & Trends By 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Drug Discovery Service Market Size Analysis

Global Drug Discovery Service Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Pharmacokinetics
  1. By Value
3. Drug Metabolism
  1. By Value
4. Biology Services
  1. By Value
5. Medicinal Chemistry
  1. By Value
6. Others
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Target Validation
  1. By Value
3. Target Selection
  1. By Value
4. Hit-To-Lead Identification
  1. By Value
5. Candidate Validation
  1. By Value
6. Lead Optimization
  1. By Value
7. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
3. Small Molecules
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Neurology
  1. By Value
3. Diabetes
  1. By Value
4. Oncology
  1. By Value
5. Respiratory Diseases
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospital & Clinics
  1. By Value
3. Pharmaceutical Companies
  1. By Value
4. Biotechnology Companies
  1. By Value
5. Research Institute
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Pharmacokinetics
  1. By Value
3. Drug Metabolism
  1. By Value
4. Biology Services
  1. By Value
5. Medicinal Chemistry
  1. By Value
6. Others
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Target Validation
  1. By Value
3. Target Selection
  1. By Value
4. Hit-To-Lead Identification
  1. By Value
5. Candidate Validation
  1. By Value
6. Lead Optimization
  1. By Value
7. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
3. Small Molecules
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Neurology
  1. By Value
3. Diabetes
  1. By Value
4. Oncology
  1. By Value
5. Respiratory Diseases
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospital & Clinics
  1. By Value
3. Pharmaceutical Companies
  1. By Value
4. Biotechnology Companies
  1. By Value
5. Research Institute
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Pharmacokinetics
    1. By Value
  3. Drug Metabolism
    1. By Value
  4. Biology Services
    1. By Value
  5. Medicinal Chemistry
    1. By Value
  6. Others
    1. By Value
2. By Process
  1. Introduction
    1. Process By Value
  2. Target Validation
    1. By Value
  3. Target Selection
    1. By Value
  4. Hit-To-Lead Identification
    1. By Value
  5. Candidate Validation
    1. By Value
  6. Lead Optimization
    1. By Value
  7. Others
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
  3. Small Molecules
    1. By Value
4. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Neurology
    1. By Value
  3. Diabetes
    1. By Value
  4. Oncology
    1. By Value
  5. Respiratory Diseases
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospital & Clinics
    1. By Value
  3. Pharmaceutical Companies
    1. By Value
  4. Biotechnology Companies
    1. By Value
  5. Research Institute
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Pharmacokinetics
  1. By Value
3. Drug Metabolism
  1. By Value
4. Biology Services
  1. By Value
5. Medicinal Chemistry
  1. By Value
6. Others
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Target Validation
  1. By Value
3. Target Selection
  1. By Value
4. Hit-To-Lead Identification
  1. By Value
5. Candidate Validation
  1. By Value
6. Lead Optimization
  1. By Value
7. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
3. Small Molecules
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Neurology
  1. By Value
3. Diabetes
  1. By Value
4. Oncology
  1. By Value
5. Respiratory Diseases
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospital & Clinics
  1. By Value
3. Pharmaceutical Companies
  1. By Value
4. Biotechnology Companies
  1. By Value
5. Research Institute
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Pharmacokinetics
    1. By Value
  3. Drug Metabolism
    1. By Value
  4. Biology Services
    1. By Value
  5. Medicinal Chemistry
    1. By Value
  6. Others
    1. By Value
2. By Process
  1. Introduction
    1. Process By Value
  2. Target Validation
    1. By Value
  3. Target Selection
    1. By Value
  4. Hit-To-Lead Identification
    1. By Value
  5. Candidate Validation
    1. By Value
  6. Lead Optimization
    1. By Value
  7. Others
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
  3. Small Molecules
    1. By Value
4. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Neurology
    1. By Value
  3. Diabetes
    1. By Value
  4. Oncology
    1. By Value
  5. Respiratory Diseases
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospital & Clinics
    1. By Value
  3. Pharmaceutical Companies
    1. By Value
  4. Biotechnology Companies
    1. By Value
  5. Research Institute
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Pharmacokinetics
  1. By Value
3. Drug Metabolism
  1. By Value
4. Biology Services
  1. By Value
5. Medicinal Chemistry
  1. By Value
6. Others
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Target Validation
  1. By Value
3. Target Selection
  1. By Value
4. Hit-To-Lead Identification
  1. By Value
5. Candidate Validation
  1. By Value
6. Lead Optimization
  1. By Value
7. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
3. Small Molecules
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Neurology
  1. By Value
3. Diabetes
  1. By Value
4. Oncology
  1. By Value
5. Respiratory Diseases
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospital & Clinics
  1. By Value
3. Pharmaceutical Companies
  1. By Value
4. Biotechnology Companies
  1. By Value
5. Research Institute
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Pharmacokinetics
    1. By Value
  3. Drug Metabolism
    1. By Value
  4. Biology Services
    1. By Value
  5. Medicinal Chemistry
    1. By Value
  6. Others
    1. By Value
2. By Process
  1. Introduction
    1. Process By Value
  2. Target Validation
    1. By Value
  3. Target Selection
    1. By Value
  4. Hit-To-Lead Identification
    1. By Value
  5. Candidate Validation
    1. By Value
  6. Lead Optimization
    1. By Value
  7. Others
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
  3. Small Molecules
    1. By Value
4. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Neurology
    1. By Value
  3. Diabetes
    1. By Value
  4. Oncology
    1. By Value
  5. Respiratory Diseases
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospital & Clinics
    1. By Value
  3. Pharmaceutical Companies
    1. By Value
  4. Biotechnology Companies
    1. By Value
  5. Research Institute
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Pharmacokinetics
  1. By Value
3. Drug Metabolism
  1. By Value
4. Biology Services
  1. By Value
5. Medicinal Chemistry
  1. By Value
6. Others
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Target Validation
  1. By Value
3. Target Selection
  1. By Value
4. Hit-To-Lead Identification
  1. By Value
5. Candidate Validation
  1. By Value
6. Lead Optimization
  1. By Value
7. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
3. Small Molecules
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Neurology
  1. By Value
3. Diabetes
  1. By Value
4. Oncology
  1. By Value
5. Respiratory Diseases
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospital & Clinics
  1. By Value
3. Pharmaceutical Companies
  1. By Value
4. Biotechnology Companies
  1. By Value
5. Research Institute
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Pharmacokinetics
    1. By Value
  3. Drug Metabolism
    1. By Value
  4. Biology Services
    1. By Value
  5. Medicinal Chemistry
    1. By Value
  6. Others
    1. By Value
2. By Process
  1. Introduction
    1. Process By Value
  2. Target Validation
    1. By Value
  3. Target Selection
    1. By Value
  4. Hit-To-Lead Identification
    1. By Value
  5. Candidate Validation
    1. By Value
  6. Lead Optimization
    1. By Value
  7. Others
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
  3. Small Molecules
    1. By Value
4. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Neurology
    1. By Value
  3. Diabetes
    1. By Value
  4. Oncology
    1. By Value
  5. Respiratory Diseases
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospital & Clinics
    1. By Value
  3. Pharmaceutical Companies
    1. By Value
  4. Biotechnology Companies
    1. By Value
  5. Research Institute
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Pharmacokinetics
  1. By Value
3. Drug Metabolism
  1. By Value
4. Biology Services
  1. By Value
5. Medicinal Chemistry
  1. By Value
6. Others
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Target Validation
  1. By Value
3. Target Selection
  1. By Value
4. Hit-To-Lead Identification
  1. By Value
5. Candidate Validation
  1. By Value
6. Lead Optimization
  1. By Value
7. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
3. Small Molecules
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Neurology
  1. By Value
3. Diabetes
  1. By Value
4. Oncology
  1. By Value
5. Respiratory Diseases
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospital & Clinics
  1. By Value
3. Pharmaceutical Companies
  1. By Value
4. Biotechnology Companies
  1. By Value
5. Research Institute
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Pharmacokinetics
    1. By Value
  3. Drug Metabolism
    1. By Value
  4. Biology Services
    1. By Value
  5. Medicinal Chemistry
    1. By Value
  6. Others
    1. By Value
2. By Process
  1. Introduction
    1. Process By Value
  2. Target Validation
    1. By Value
  3. Target Selection
    1. By Value
  4. Hit-To-Lead Identification
    1. By Value
  5. Candidate Validation
    1. By Value
  6. Lead Optimization
    1. By Value
  7. Others
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
  3. Small Molecules
    1. By Value
4. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Neurology
    1. By Value
  3. Diabetes
    1. By Value
  4. Oncology
    1. By Value
  5. Respiratory Diseases
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospital & Clinics
    1. By Value
  3. Pharmaceutical Companies
    1. By Value
  4. Biotechnology Companies
    1. By Value
  5. Research Institute
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Drug Discovery Service Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Thermo Fisher Scientific, Inc.(The U.S.)
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Albany Molecular Research, Inc. (The U.S.)
Charles River Laboratories International, Inc. (The U.S.)
Evotec A.G. (Germany)
Domainex (UK)
GenScript Biotech Corporation (China)
Laboratory Corporation of America Holdings (The U.S.)
WuXi AppTec (China)
Pharmaceutical Product Development, LLC (The U.S.)
Jubilant Biosys Ltd. (India)
Eurofins Scientific SE (Luxembourg)
Piramal Enterprises Ltd. (India)

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment